Tove Kirkegaard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10418180/publications.pdf

Version: 2024-02-01

840776 1199594 1,014 12 11 12 citations h-index g-index papers 12 12 12 1475 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer. Clinical Cancer Research, 2016, 22, 5514-5526.	7.0	57
2	T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant. Cancer Letters, 2014, 344, 90-100.	7.2	23
3	Molecular alterations in <i>AKT1</i> , <i>AKT2</i> and <i>AKT3</i> detected in breast and prostatic cancer by FISH. Histopathology, 2010, 56, 203-211.	2.9	41
4	Expression of Tumor Necrosis Factor \hat{l}_{\pm} Converting Enzyme in Endocrine Cancers. American Journal of Clinical Pathology, 2008, 129, 735-743.	0.7	9
5	Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor–Positive Tumors of Tamoxifen-Treated Breast Cancer Patients. Clinical Cancer Research, 2007, 13, 1405-1411.	7.0	105
6	Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Research and Treatment, 2007, 102, 173-179.	2.5	41
7	AKT activation predicts outcome in breast cancer patients treated with tamoxifen. Journal of Pathology, 2005, 207, 139-146.	4.5	250
8	Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption. Bone, 2004, 34, 37-47.	2.9	87
9	A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. Bone, 2004, 35, 1107-1119.	2.9	131
10	Engineering of conformations of plasminogen activator inhibitor-1. A crucial role of beta-strand 5A residues in the transition of active form to latent and substrate forms. FEBS Journal, 1999, 263, 577-586.	0.2	13
11	Kinetic analysis of integrin-dependent cell adhesion on vitronectin. The inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides. FEBS Journal, 1998, 253, 669-674.	0.2	36
12	Plasminogen Activator Inhibitor-1 Represses Integrin- and Vitronectin-Mediated Cell Migration Independently of Its Function as an Inhibitor of Plasminogen Activation. Experimental Cell Research, 1997, 232, 420-429.	2.6	221